Company News

Cyclopharm (ASX:CYC) has reached a significant milestone in the global adoption of its flagship lung imaging technology, with Technegas formally recognised as a preferred ventilation agent in a newly released international clinical guideline for lung imaging.

Aroa Biosurgery (ASX:ARX) has published new clinical evidence demonstrating both the effectiveness and economic value of its Myriad products in complex trauma and acute care surgery, reinforcing the growing role of the company’s bioscaffold technology in high-acuity surgical settings.

BCAL Diagnostics (ASX:BDX) has strengthened its board with the appointment of experienced healthcare technology executive Mark McConnell as a Non-Executive Director, effective 1 February 2026.

OncoSil Medical (ASX:OSL) has reached a significant milestone in its European growth strategy, with the first OncoSil treatment successfully performed at Vivantes Neukölln Hospital in Berlin.

Nexsen has taken a significant step toward expanding its impact in global healthcare, securing a $500,000 non-dilutive Federal Government grant to extend its Group B Streptococcus rapid diagnostic technology into neonatal care.

Compumedics (ASX:CMP) has delivered a strong first half performance in the 2026 financial year, marked by record sales orders, a substantial uplift in shipped revenue, and improving earnings momentum.

Clinical-stage biotechnology company Noxopharm (ASX:NOX) has successfully completed the second and final multiple-dose cohort of its SOF-SKN clinical program, marking the conclusion of the clinical phase of the HERACLES trial and delivering a highly positive safety outcome.

As Australia’s life sciences sector deepens its global engagement, the need to manage foreign interference risks has become an increasingly important consideration for organisations operating across borders.

Telix Pharmaceuticals (ASX:TLX) has closed the 2025 financial year, having met its upgraded revenue guidance, underscoring the accelerating commercial momentum of its precision medicine portfolio and the growing impact of its U.S. expansion strategy.

Australia’s life sciences sector is entering 2026 with a renewed emphasis on structured expertise and member-led advocacy, following AusBiotech's refresh of its Advisory Groups to strengthen the organisation's engagement with industry and government.

Neurizon Therapeutics (ASX:NUZ) has announced the successful registration of its NEURIZON trademark across all major pharmaceutical markets.

Mesoblast (ASX:MSB) announced that the U.S. FDA acknowledged that clinical trial data demonstrate meaningful and sustained reductions in chronic low back pain, with the potential to reduce accompanying opioid use.